Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) has announced the appointment of David H. Clarke as a Strategic Advisor to the company's executive management team.

Randy Milby, CEO of Tharimmune, stated, "David's wide-ranging accomplishments and business insight will meaningfully strengthen our organization. His understanding of publicly traded company operations and leadership skills will provide strategic guidance as we advance TH104 for treating pruritus in primary biliary cholangitis and expand our pipeline."

Mr. Clarke brings extensive experience, having led and served on the boards of several international and U.S.-based organizations. His expertise in corporate governance, financial and strategic planning, and investing in multiple industries, including biotechnology, enhances Tharimmune's commitment to delivering innovative treatments.

"I look forward to supporting the Tharimmune team," said Mr. Clarke. "Their innovative approach, growth prospects, and commitment to advancing treatments for underserved conditions align with my interests and expertise."

Mr. Clarke has over three decades of executive leadership experience. He previously served as Chairman and CEO of United Pacific Industries and NYSE-listed Jacuzzi Brands. He also held senior roles at London-based Hanson PLC. Currently, he oversees various business interests through his family holding company and invests in biotechnology companies.